The World Health Organization (WHO) COVD-19 Vaccine Advisory Group has recommended the use of Novavax’s monovalent JN.1 lineage COVID-19 vaccine as an approach to address the ongoing evolution of the SARS-CoV-2 virus, which should lead to the circulation of strains descended from JN.1.
Novavax has indicated that it plans to be ready to make its non-mRNA COVID-19 vaccine based on the JN.1 protein globally available next fall.
Biotechnology company Novavax clarified: “Our most recent non-clinical data demonstrated that our vaccine candidate JN.1 induces neutralization responses to strains JN.1, JN.4, JN.1.11.1, JN.1.7, JN .1.13.1 and JN.1.16.”
He added: “Our JN.1 vaccine candidate also produces polyfunctional CD4+ T cell cellular responses to a variety of omicron strains, including JN.1 and JN.1.11. These responses once again indicate that our vaccine technology can induce broadly neutralizing responses against multiple variant strains, including circulating drift variants.”
